

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 9/50, 9/14, 9/127, 47/24, 31/65, 31/706, 31/538, 31/496, 31/545, 31/546, 31/425, 31/05, 31/44, A61P 31/00, 29/00	A1	(11) International Publication Number: WO 00/27369 (43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/US99/26452 (22) International Filing Date: 8 November 1999 (08.11.99) (30) Priority Data: 09/190,049 10 November 1998 (10.11.98) US (71) Applicant (for all designated States except US): IDEXX LABORATORIES, INC. [US/US]; One Idexx Drive, Westbrook, ME 04092 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LARSON, Kenneth, A. [US/US]; 1305 Teakwood, Fort Collins, CO 80525 (US). CAMPBELL, William, R. [US/US]; P.O. Box 1016, Jamestown, NC 27282 (US). HEPLER, Douglas, I. [US/US]; 815 Cliff Drive, McLeansville, NC 27301 (US). (74) Agent: CONSALVI, Mary, S.; Lyon & Lyon LLP, 633 West Fifth Street, Suite 4700, Los Angeles, CA 90071-2066 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: PHOSPHOLIPID-COATED MICROCRYSTALS FOR THE SUSTAINED RELEASE OF PHARMACOLOGICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR MANUFACTURE AND USE

(57) Abstract

The present invention relates to pharmaceutical compositions for the sustained release of pharmacologically active compounds, and methods of their manufacture and use. The pharmaceutical compositions contain microcrystals of pharmacologically active compounds which are encapsulated within a phospholipid layer which contains a unique combination of phospholipids. The pharmaceutical compositions may be rendered suitable for injection. The microcrystals are of varying sizes. At least 50 percent of the microcrystals are from 0.5 μm and 3.0 μm in diameter, at least ten percent of the microcrystals are from 3.0 μm to 10 μm in diameter, and the composition contains microcrystals which are greater than 10 μm in diameter. The methods disclosed contain the steps of forming a lipid suspension which contains the pharmacologically active compound and passing the lipid suspension with the pharmacologically active compound through a homogenizer at high pressure to coat the compound with the lipid suspension, thereby producing water insoluble drugs coated with the lipid suspension. The method is applicable to antibiotics, anti-inflammatory agents, anesthetics, anti-protozoa agents or any compound, including water soluble compounds, which can be modified so as to behave more like water insoluble compounds. The compositions and methods are useful for treating respiratory diseases in a variety of mammals. The compounds and methods are also able to sharply reduce the toxicity of drug compounds.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

WO 00/27369

PCT/US99/26452

1

DESCRIPTION

Phospholipid-coated microcrystals for the sustained Release of pharmacologically active compounds and Methods of their manufacture and use

Background Of The Invention

5 It is known that water insoluble drugs can be rendered injectable by formulating them into aqueous suspensions of phospholipid-coated microcrystals. Haynes, U.S. Patent No. 5,091,188 and U.S. Patent No. 5,091,187, disclosed a method of coating pharmaceutical compounds with a phospholipid layer that makes water insoluble drugs able to be contained within an aqueous medium, and therefore suitable for injection in a mammal.

10 Baurain et al., U.S. Patent No. 4,973,467 describes the preparation of microcrystals of ginkgolide B, kadsurenone, amphotericin B, and nystatin. Baurain et al. prepared microcrystals by the common method of forming a lipid film in a flask by dissolving the lipids to be used in organic solvent, evaporating the solvent, and then sonicating in the presence of the active compound to produce microcrystals sized between 0.1 μm and 2 μm .

20 Animal husbandry operations which manage large numbers of animals have been unable to realize the benefits of the prior technology because it has not been successfully applied on a large scale. The procedures disclosed by Haynes and others have had limited commercial practicability since the methods involve the use of sonication or other processes which are inappropriate or impractical for producing commercially advantageous quantities of product.

25 The present invention provides a method suitable for economically producing yields of up to thousands of liters of pharmaceutical compositions for the sustained release of a pharmacologically active compound. The method can be applied with a commercial scale homogenizer, or any instrument or technique which provides the necessary forces to effectively coat the pharmacologically active compound with the lipid suspension.

30 Furthermore, the compositions of the prior art have relied on commonly available forms of phospholipid mixtures which are highly purified and prohibitively expensive for use on a commercial scale. The present invention discloses a method for isolating a composition of lipids from egg yolk which results in a suspension of lipids which can be economically produced, and can be used to coat a pharmacologically active compound to produce the microcrystals of the present invention. These microcrystals exhibit several beneficial characteristics, including a longer sustained release time and the ability to

WO 00/27369

PCT/US99/26452

2

sharply decrease the toxicity of drug compounds. These microcrystals may be formed into an injectable suspension for subcutaneous injection into a mammal. The suspension may be syringeable and therefore suitable for subcutaneous injection.

One skilled in the art will realize that the microcrystals of this invention can be administered to the mammal in a variety of other ways including, but not limited to, skin patches, ocular inserts, shooting through the skin at high velocity with a medical "air gun," suppositories, or simply providing the compounds in a mammal's food and water.

It has been previously thought that it is desirable to produce a composition of microcrystals having homogeneous microcrystals of a very small size. Previously, it has been believed that it is desirable to produce microcrystals below 1 μm , or at least below 2 μm or 3 μm . The present invention discloses that unexpected benefits, including benefits in timed release delivery, can be realized by producing a composition which contains microcrystals of varying sizes. The present invention discloses compositions wherein at least 50 percent of the microcrystals are from about 0.5 μm to about 3.0 μm in diameter, at least ten percent of the microcrystals are from about 3.0 μm to about 10 μm in diameter, and the compositions contain microcrystals which are greater than about 10 μm in diameter. In a preferred embodiment, at least about 50 percent of the microcrystals will be from about 0.5 μm to about 3 μm in diameter, from about thirty to about forty percent of the microcrystals will be from about 3 μm to about 10 μm in diameter, and the composition contains microcrystals which are greater than about 10 μm in diameter. We have found that by utilizing microcrystals of these varying sizes sustained release times of as long as 10-12 days can be obtained. The person of skill in the art will readily realize that even presently known lipid compositions may be put into the novel compositions claimed herein to realize these benefits. The invention teaches novel compositions which are mixtures of microcrystals of varying sizes as disclosed herein.

The present invention also discloses methods for treating infections in mammals. In preferred embodiments, methods are provided for treating respiratory diseases in mammals, in particular, infections of the respiratory tract. In particularly preferred embodiments, methods are provided for treating bovine respiratory disease (commonly known as "shipping fever"), kennel cough in dogs, and Potomac fever in horses. In another particularly preferred embodiment, methods are provided for treating infections of the respiratory tract in cats.

Prior methods of treating infections in animals have centered on the regular and repeated administration of antibiotics to the mammal until the infection was eradicated, sometimes by incorporating the drug into the animal's food or water, by oral administration in a paste or with a balling gun, or by repeated injections. Therapeutic

WO 00/27369

PCT/US99/26452

3

regimens often failed due to a failure on the part of the animal owner to follow the prescribed regimen. The present invention provides a method of treating infections which requires only a single administration of the microcrystal compositions of the present invention. The microcrystal composition may be an injectable syringeable suspension.

5 The administration can be delivered by an animal care professional and does not require further participation by the owner for a successful result of the therapy, thereby eliminating issues of therapy noncompliance by the owner as a reason for failure of the therapy. The present methods are applicable to a variety of mammals including, but not limited to, bovines, equines, porcines, canines, and felines. The person of skill in the art

10 will readily realize that the methods herein disclosed will find applicability to a wide variety of mammals.

The person of skill in the art will also readily realize that the compositions and techniques described herein can be applied to a wide variety of pharmacologically active compounds. Various antibiotics, anesthetics, anti-inflammatory agents, and anti-

15 protozoan agents may all be incorporated into a microcrystal suspension, as may other chemical compounds of varied uses which will be apparent to those of skill in the art.

We have also observed that pharmacologically active compounds which are coated with the phospholipid composition of the present invention are able to attach to blood cells. In this case the pharmacologically active compound is found associated with the

20 blood cells in blood analysis assays. This characteristic of the microcrystals of the present invention serves to facilitate the delivery of pharmacologically active compound to the body tissues.

Summary Of Invention

The present invention realizes a substantial advance in the field of microcrystal

25 technology by providing novel lipid compositions for coating microcrystals of useful drugs. These novel compositions result in pharmaceutical suspensions containing phospholipid coated microcrystals which offer significantly longer sustained release times than those of the prior art. These compositions offer the additional and important benefit of sharply reducing the toxicity of many useful pharmaceutical compounds which are

30 underutilized due to concerns about their toxicity.

The present invention also provides new methods for manufacturing suspensions of microcrystals which contain pharmaceutically active compounds encapsulated in a phospholipid layer on a commercial scale. The suspensions may be made suitable for injection. Various water insoluble and pharmaceutically active compounds may be

35 produced in the form of these phospholipid coated microcrystals. The methods are

WO 00/27369

PCT/US99/26452

4

suitable for producing thousands of liters of microcrystal product, allowing the technology to be utilized on a commercial scale.

The present invention also provides methods for treating infections in a variety of mammals which involve the administration of the microcrystals produced by these methods. In preferred embodiments, the infection may be a bacterial, fungal, protozoa, or any type of parasitic organism which has invaded the body. In a preferred embodiment, the microcrystal suspension may be made into an injectable syringeable suspension and the administration accomplished by subcutaneous injection. These methods offer the distinct advantages of effective single dose therapies to cure infections, eliminate noncompliance as a barrier to drug efficacy, sharply decrease the toxicity of drug compounds, and avoid further stress and discomfort to the treated animal.

The present invention is directed towards novel pharmaceutical compositions for the sustained release of pharmacologically active compounds, and methods of their manufacture. The pharmaceutical compositions contain microcrystals of pharmacologically active compounds which are encapsulated within a phospholipid bilayer. The phospholipid bilayer contains a unique combination of phospholipids which imparts unexpected beneficial properties.

In particular, the present invention provides a composition of lipids used in coating a pharmacologically active compound which is from about 40 percent to about 80 percent by weight of phosphatidylcholine, and from about 10 percent to about 30 percent by weight of phosphatidylethanolamine. In preferred embodiments, the composition will comprise from about 50 percent to about 68 percent by weight phosphatidylcholine, and from about 15 percent to about 25 percent by weight phosphatidyl-ethanolamine.

The present invention also provides pharmaceutical compositions which contain a suspension of microcrystals contained within a phospholipid layer which is made of any of the compositions of lipids described above. The microcrystals are a solid, crystalline form of the particular pharmacologically active compound of interest. The suspension may be made suitable for injection into a mammal, and may be made syringeable as well.

The present invention also provides pharmaceutical suspensions of microcrystals which contain a pharmacologically active compound contained within a phospholipid layer. In this aspect, at least about fifty percent of the microcrystals are from about 0.5 μm to about 3.0 μm in diameter, at least about 10 percent of the microcrystals are from about 3 μm to about 10 μm in diameter, and at least about 90 percent of the microcrystals are less than about 10 μm in diameter. The suspension also contains microcrystals which are greater than about 10 μm in diameter. In a preferred embodiment, at least about fifty percent of the microcrystals are from about 0.5 μm to about 3.0 μm in diameter, from

WO 00/27369

PCT/US99/26452

5

about thirty to about 40 percent of the microcrystals are from about 3.0 μm to about 10 μm in diameter, and the suspension contains microcrystals which are greater than about 10 μm in diameter. In a particularly preferred embodiment, at least about 1 percent of the microcrystals are greater than about 10 μm in diameter.

5 The present invention also provides methods of manufacturing the pharmaceutical compositions of the present invention for the sustained release of pharmacologically active compounds. The compositions contain microcrystals which contain pharmacologically active compounds contained within a phospholipid layer. The method includes the steps of forming a lipid suspension which contains the pharmacologically active compound and
10 passing the lipid suspension with the pharmacologically active compound through a homogenizer at high pressure to coat the compound with the lipid suspension and produce a suspension of microcrystals where at least about fifty percent of the microcrystals are from about 0.5 μm to about 3 μm in diameter, and at least about ten percent of the microcrystals are from about 3 μm to about 10 μm in diameter, and the suspension
15 contains microcrystals which are greater than about 10 μm in diameter. In a preferred embodiment, at least about 25 percent of the microcrystals will be greater than about 3 μm in diameter. In another preferred embodiment, at least about 25 percent of the microcrystals will be from about 3 μm to about 10 μm in diameter.

20 In another aspect, there are provided methods for manufacturing the pharmaceutical compositions of the present invention for the sustained release of pharmacologically active compounds. The compositions contain microcrystals which contain pharmacologically active compounds contained within a phospholipid layer. The methods include the steps of forming a lipid suspension, and contacting the lipid suspension with the pharmacologically active compound to coat the pharmacologically
25 active compound with the lipid suspension and produce a suspension of microcrystals where at least about fifty percent of the microcrystals are from about 0.5 μm to about 3 μm in diameter, and at least about ten percent of the microcrystals are from about 3 μm to about 10 μm in diameter, and the suspension contains microcrystals which are greater than about 10 μm in diameter. In a preferred embodiment, at least about 25 percent of the
30 microcrystals will be greater than about 3 μm in diameter. In other preferred embodiments, at least about 25 percent of the microcrystals will be from about 3 μm to about 10 μm in diameter.

35 The method produces water insoluble drugs which are coated with the phospholipid suspension and which have been modified such that they can be safely injected and have a sustained release from an injection site in a mammal, and provide an effective therapy for a variety of disease states. The microcrystals can be produced within

WO 00/27369

PCT/US99/26452

6

the above stated size distribution range which serves to increase the sustained release time of the pharmacologically active compound they contain.

In one embodiment of the method, the lipid suspension is passed through a homogenizer repeatedly at high pressure. In a preferred embodiment, it is passed through a homogenizer three times at high pressure. In other embodiments, the lipid suspension may be passed through a homogenizer a number of times necessary to obtain a microcrystal suspension which lacks clumping, contains particles within the desired size ranges indicated above, and is free-flowing.

The pharmacologically active compound may be an antibiotic. The antibiotic may be a cephalone, tilmicosin, or nitazoxanide. The antibiotic may also be a fluoroquinolone such as ofloxacin, sarafloxacin, or ciprofloxacin. The antibiotic may also be a cephalosporin such as cefazolin, cefuroxime or a derivative of cefuroxime, cefoperazone, or cefaclor. In other embodiments, the antibiotic may be a tetracycline such as oxytetracycline. The pharmacologically active compound may also be a fluoroquinolone and a cephalosporin which have been combined to form a single molecule. The pharmacologically active compound may also be an anti-inflammatory agent, such as flunixin. In other embodiments, the pharmaceutical composition may be an anesthetic, such as propofol, or an anti-protozoan agent, such as nitazoxanide. The suspension of microcrystals produced by the manufacturing method may also be sterilized with radiation or another sterilization method. In a preferred embodiment, the suspension of microcrystals is sterilized with gamma radiation. Persons of skill in the art will readily see that the techniques and principles disclosed can be applied to a variety of water insoluble pharmaceutical products and chemicals to produce microcrystals which are useful for a wide variety of purposes. The techniques and principles may also be applied to water soluble compounds which have been modified in order to behave more like water insoluble compounds.

The pharmacologically active compounds described above have formal, chemical names which are hereby provided for reference. Tilmicosin is chemically known as 20-deoxo-20-(3,5-dimethyl piperidinyl)-1-yl desmycosin. Ciprofloxacin is chemically known as 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid. Cefazolin is chemically known as [(6R-trans)-3[[5-methyl-1,3,4-thiadiazol-2-yl) thio]methyl]-8-oxo-7-[(1H-tetrazol-1-yl acetyl)-amino]-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid. Cefaclor is chemically known as 7-[(aminophenylacetyl)amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid. Cefoperazone is chemically known as 7-[D-(-)- α -(4-ethyl-2,3-dioxo-1-piperzine carboxamido)- α -(4-hydroxyphenyl) acetamido]-3[[1-methyl-1H-tetra-zol-5-yl) thio]methyl]-3-cephem-4-

WO 00/27369

PCT/US99/26452

7

carboxylic acid. Cefuroxime is chemically known as [6R-[6 α ,7 β (Z)]]-3-
[[[aminocarbonyl]oxy]methyl]-7-[[2-furanyl(methoxyimino) acetyl] amino]-8-oxo-5-thia-
1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid. Oxytetracycline is chemically known as
4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-
5 methyl-1,11-dioxo-2-naphthalenecarboxamide. Ofloxacin is chemically known as (\pm)-9-
fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido-[1,2,3-de]-
1,4-benzoxazine-6-carboxylic acid. Flunixin is chemically known as 2-[[2-methyl-3-
(trifluoromethyl) phenyl]amino]-3-pyridine carboxylic acid. Propofal is chemically
known as 2,6-bis(1-methylethyl) phenol. Cephalone (cephaquinolone) is chemically
10 known as 7[(1-cyclopropyl-6-fluoro-7-(4-ethyl piperazine-1-yl)-1, 4 dihydro-4-
oxoquinoline-3-yl) carboxamido] cefalosporanic acid. Nitazoxanide (NTZ) is chemically
known as 2-(acetyloxy)-N-(5-nitro-2-thiazolyl) benzamide. Sarafloxacin is chemically
known as 6-Fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-
quinolinecarboxylic acid.

15 The present invention also provides a method for treating an infection in a
mammal. The method contains the steps of administering to the mammal an effective
dose of a suspension containing microcrystals which contains a pharmacologically active
compound within a phospholipid layer. At least about 50 percent of the microcrystals are
from about 0.5 μ m to about 3 μ m in diameter, at least about ten percent of the
20 microcrystals are from about 3 μ m to about 10 μ m in diameter, and the suspension
contains microcrystals that are greater than about 10 μ m in diameter. In a preferred
embodiment, at least about 25 percent of the microcrystals will be from about 3 μ m to
about 10 μ m.

In preferred embodiments, the pharmacologically active compound may be any of
25 the pharmacologically active compounds described herein.

In a preferred embodiment, the infection may be a respiratory disease and may be
treated with microcrystals containing any of the above named compounds. In a
particularly preferred embodiment, the infection may be bovine respiratory disease and the
pharmacologically active compound may be oxytetracycline. In another particularly
30 preferred embodiment, the disease may be "kennel cough," the mammal a canine, and the
pharmacologically active compound tilimicosin.

The infection may also be caused by a protozoa and the microcrystal may contain
an anti-protozoa agent such as nitazoxanide (NTZ). The infection may also be caused by a
fungus and the pharmacologically active compound contained in the microcrystal may be
35 an anti-fungal agent. The person of skill in the art will readily see that the microcrystals

WO 00/27369

PCT/US99/26452

8

may contain a wide variety of pharmacologically active compounds which may be used to treat a wide variety of diseases.

In preferred embodiments, the suspensions of the present invention may be made into an injectable syringeable form and administered to the mammal by parenteral administration. The mammal may be a bovine, an equine, a porcine, a canine, a feline, or any mammal.

In another aspect, the invention provides a method for treating inflammation in a mammal. In this aspect, the pharmacologically active compound will be an anti-inflammatory agent contained within a phospholipid layer. In a preferred embodiment, the anti-inflammatory agent may be flunixin.

In another aspect of the invention, the above method may be a method for treating pain in a mammal. In this aspect, the microcrystals contain an anesthetic. In a preferred embodiment, the anesthetic may be propofol. All of the pharmaceutical compounds described herein may be made into a syringeable injectable form and administered to the mammal parenterally.

The present invention also provides a method for isolating from a lipid source a composition of lipids suitable for coating microcrystals. The method includes the steps of performing a lipid extraction on the lipid source with acetone, and a lipid extraction on the lipid source with ethyl alcohol. In a preferred embodiment, the lipid source is egg yolk.

The present invention also provides a pharmaceutical composition which contains microcrystals, which are compositionally from about 10 percent to about 30 percent by weight of a pharmacologically active compound, and from about 15 percent to about 30 percent of a phospholipid syrup. In a preferred embodiment, the microcrystals may be compositionally from about 25 percent to about 30 percent by weight of a pharmacologically active compound, and about 20 percent of a phospholipid syrup. In a preferred embodiment, the pharmacologically active compound may be an antibiotic, such as oxytetracycline. In other embodiments, the pharmacologically active compound may be any of the compounds described herein.

The person of skill in the art will realize that the techniques and principles disclosed can be used to treat a variety of diseases in many types of mammals.

Brief Description Of The Drawings

Fig. 1 is a schematic drawing of the process of manufacturing injectable syringeable pharmaceutical suspension for the sustained release of pharmacologically active compounds of the present invention;

WO 00/27369

PCT/US99/26452

9

Figure 2 is a graphical illustration the mean serum and lung tissue concentrations in cows of OTC as a function of time;

Figure 3 is a graphical illustration of levels of tilmicosin in the blood serum in dogs after administration of 20 mg/kg of microcrystals containing tilmicosin;

5 Figure 4 is a graphical illustration of levels of tilmicosin in the blood cells of dogs after administration of 20 mg/kg of microcrystals containing tilmicosin; and

Figure 5 is a graphical illustration of levels of tilmicosin in six types of body tissue in dogs, pigs, and cats six days after the administration of 20 mg/kg of microcrystals containing tilmicosin. Data is presented in a parts per million v. type of tissue format.

10 Detailed Description Of The Invention

The present invention relates to a new technology for the manufacture of sustained release pharmaceutical compositions, particularly as applied to water insoluble drugs in a veterinary context. The compositions may be provided as suspensions in an injectable syringeable form. The invention provides for the manufacture of microcrystals which
15 contain from about 10 percent to about 30 percent (w/v) of an antibiotic or other pharmacologically active compound as the active ingredient, and from about 15 percent to about 30 percent (w/v) of phospholipids syrup as dispersing agent. The suspension products may be terminally sterilized by gamma radiation. In a preferred embodiment the suspension may contain microcrystals which contain from about 25 percent to about 30
20 percent (w/v) of a pharmacologically active compound (OTC), and about 20 percent (w/v) phospholipids syrup. In a preferred embodiment, the pharmacologically active compound is oxytetracycline (OTC). (We have found that this higher percentage of OTC results in a more concentrated depot of medication which has resulted in a longer release time for the drug into the blood of the treated animal. We have also found that the higher
25 concentration of OTC enables the use of a smaller volume of pharmaceutical suspension, thus decreasing stress on the animal.

The antibiotic-containing suspensions are sustained release formulations which are effective for the treatment of various diseases. There are provided methods for the manufacture of suspensions containing microcrystals which contain numerous antibiotics,
30 including tilmicosin, cephalone, ofloxacin, cefazolin, cefuroxime and its derivatives, cefoperazone, cefaclor, sarafloxacin, NTZ, and ciprofloxacin. Other methods are provided for the manufacture of microcrystals which contain anti-inflammatory agents such as flunixin, anesthetics such as propofal, and anti-protozoan agents such as nitazoxanide. The suspensions may be provided in a syringeable injectable form. The dose may be
35 calculated on a per pound basis. The suspension dose may be administered

WO 00/27369

PCT/US99/26452

10

subcutaneously per injection for the required number of injections in different skin regions per treatment. In cows, more than one injection may be required, whereas in other mammals such as dogs, cats, or pigs a single injection of the antibiotic may be effective to achieve the therapeutic objective. The injection(s) can provide therapeutic tissue levels of pharmacologically active compound over periods of up to 10-12 days.

Water insoluble drugs may be rendered injectable by formulating as aqueous suspensions of phospholipid-coated antibiotic microcrystals for veterinary subcutaneous administration. The membrane phospholipid stabilizes the microcrystals by both hydrophobic and hydrophilic interactions.

We have also unexpectedly found that the microcrystals of the present invention offer the additional advantage of sharply reducing the toxicity of certain pharmacologically active compounds, rendering these compounds safe to use. For example, there has been a great hesitancy to use drugs such as tilmicosin and flunixin because of their known toxic effects. Similar concerns surround the use of oxytetracycline in horses and cows. We have unexpectedly found that tilmicosin and flunixin can be safely injected into cats, dogs, and pigs when they are coated with the phospholipid compositions of the present invention. Oxytetracycline can also be rendered much safer for horses and cows when coated with these compositions. Therefore, the present invention makes available to the animal caretaker drug products which were formerly underutilized due to concerns over animal safety. The present invention also provides a new tool to animal caretakers dealing with resistant strains of organisms since previously underutilized antibiotics can be used with greater confidence.

Effects of Utilizing a Range of Microcrystal Sizes

An important aspect of the present invention is the fact that homogenization at high pressure of solid particles of pharmacologically active compounds, such as antibiotics or other drugs, with a lipid suspension produces a thorough and complete coating of the solid particles with the lipid suspension. We have unexpectedly found that if the homogenization processing is stopped at a point where the microcrystals exist in a range of particle sizes, a suspension can be produced which offers the benefit of longer release times when injected into mammals. It was previously believed that it was desirable to produce microcrystals in the size range of 0.1 μm to 3 μm , with a preference for microcrystals below 1 μm in diameter. However, we have unexpectedly found that longer release times can be obtained by stopping the homogenization process at a point when more than at least about 50 percent of the microcrystals are from about 0.5 μm to about 3.0 μm in diameter, at least about ten percent of the microcrystals are from about 3 μm to

WO 00/27369

PCT/US99/26452

11

about 10 μm in diameter, and at least about 90% of the microcrystals produced are less than about 10 μm in diameter. In preferred embodiments, at least about 50 percent of the microcrystals are from about 0.5 μm to about 3 μm in diameter, from about 30 percent to about 40 percent of the microcrystals are from about 3.0 μm to about 10 μm in diameter, and the suspension contains microcrystals which are greater than about 10 μm in diameter. In a particularly preferred embodiment, at least about one percent of the microcrystals are greater than about 10 μm in diameter. We have unexpectedly found that the release times of diffusion from an injection "depot" into the blood to the infection site by the pharmacologically active compounds contained by the microcrystals can be increased by obtaining suspensions which contain microcrystals of these varying sizes.

While not wanting to be bound by any particular theory or principle, it is also believed that the unique lipid composition disclosed herein may play an important role in realizing the sustained release times we have obtained. It is also thought that it may be a combination of the unique particle sizes and the novel lipid compositions of the present invention which combine to enable the realization of these benefits.

Longer Treatment Intervals

The longer sustained release times which have been attainable with the compositions and methods of the present invention result in important advantages. We have achieved sustained release times of 10-12 days in cattle and 7 days in dogs, cats, and swine. Dogs and cats can be treated with a single administration thus eliminating issues of therapy noncompliance by owners, a major reason for failure of a therapeutic regimen. Cattle can be treated once every 10-12 days as opposed to presently available methods and compounds which require treatment at intervals of about 3-5 days. Therefore, the present invention offers the additional benefit of cost savings to the animal owners and substantially decreased stress on the animals, which are treated at less frequent intervals, or a single time.

Therefore, using the compositions and methods disclosed herein, we have been able to realize the useful benefits of microcrystal technology, and have shown the efficacy of these novel pharmaceutical products and obtained release times longer than any others thus far available. Since homogenization can be conveniently practiced on a large scale using industrial-sized homogenizers, this invention makes available methods of producing microcrystals of useful pharmacologically active compounds on a large, commercially viable scale where up to thousands of liters of material can be conveniently and economically produced.

WO 00/27369

PCT/US99/26452

12

In the manufacturing process, the temperature of the suspension increases during homogenization. We have found that the consistency of the suspension is not acceptable at a processing temperature greater than 60°C, and preferably should be processed below 50°C.

5 In a preferred embodiment of the invention, the suspension contains microcrystals of oxytetracycline. This suspension is very useful for the treatment of bovine respiratory disease. The person of skill in the art will realize that the principles and techniques disclosed herein can be applied to a variety of compounds in many contexts. Even water
10 soluble compounds can be chemically modified so as to behave more like water insoluble compounds. This can be accomplished by a change in pH or by covalent modification of the molecule or by complexation with various molecules which are used in the art to decrease the water soluble properties of a molecule. The person of ordinary skill will realize that the principles and techniques described herein will also find application to
15 some water soluble compounds which have been modified so as to chemically behave more like water insoluble compounds, and will know of various methods which are available to modify water soluble compounds to make them chemically behave more like water insoluble compounds.

The Homogenizer

We have achieved success in manufacturing the microcrystals of the present
20 invention with a homogenizer from APV Gaulin Rannie, Wilmington, Massachusetts, Model MS18-10TBS, which was operated according to the manufacturer's instructions. We were unable to achieve the desired level of coating of microcrystals with homogenizers of other manufacturers which operate according to a principle of agitation with a probe with blades and stirring.

25 While not wanting to be bound by a single theory or operating principle, it is believed that the properties of the homogenizer which are needed to successfully conduct the method are that the suspension is forced through a very small aperture under pressure, as opposed to those homogenizers which work according to a "chop and blend" principle. It is believed that the shear forces generated by the pressures involved combined with the
30 forcing of the crystalline particles through the small aperture facilitates the coating of the crystalline form of the pharmacologically active compound with the composition of phospholipid syrup. In a preferred embodiment, the process is conducted with pressures of above 10,000 psi which reduces the size of the microcrystals. In embodiments where the suspension will be injected into the mammal, it is important that the homogenizer
35 produce a material which is flowable, lacks clumps, and contains microcrystals in the size

WO 00/27369

PCT/US99/26452

13

ranges disclosed herein. As we have stated, in a preferred embodiment, the homogenizer produces microcrystals which are of a variety of sizes, at least about 90% of which are less than about 10 μm in diameter. More than about 50 percent of the microcrystals will be from about 0.5 μm to about 3 μm in diameter, and the composition will contain
5 microcrystals greater than about 10 μm in diameter. In preferred embodiments, a substantial portion, usually from about 30 percent to about 40 percent will be from about 3 μm to about 10 μm in diameter. In another particularly preferred embodiment, approximately 1-2%, will be greater than about 10 μm in diameter. This range of sizes is very beneficial for obtaining longer sustained release times than have been previously
10 available. As the homogenizer forces the material through the apertures and breaks up any clumps which are present, it also coats the solid particles with the lipid composition. Any homogenizer which operates according to the same principles as the Gaulin Homogenizer should produce microcrystals which can be effectively used to practice the present inventions.

15 A person of skill in the art will realize that other instruments operating under a variety of principles may be used to produce the microcrystals described herein, as long as they produce a suspension which is flowable, lacks clumping, thoroughly coats the microcrystals with the lipid composition, and are able to produce microcrystals of the sizes described herein. Useful, though not optimal, microcrystals may also be obtained by
20 utilizing the novel lipid composition described above with microcrystals described in the prior art. However, the benefit of being able to economically produce microcrystal suspensions on a commercially viable scale will be realized, as well as sustained release times which may be realized with the novel lipid composition disclosed herein.

Other benefits are also obtainable with the compositions and methods of the
25 present invention. We have found that microcrystals of the present invention are able to be taken up by or attach to blood cells. While not wanting to be limited or bound by any particular theory, it is believed that the phospholipid compositions of the present invention enables the crystalline drug compounds to be taken up by or associated with blood cells by either being recognized by the blood cell as a compound to be taken into the cell, by
30 associating with or becoming embedded within the cell membrane, or by van der Waals forces. It may be that the microcrystals become associated with the blood cells by a combination of these factors, or by other, presently unknown factors. However, the microcrystals of the present invention are associated with blood cells in blood analysis assays.

WO 00/27369

PCT/US99/26452

14

The invention is further illustrated through the following examples. These examples are not intended to be limiting. The person of skill in the art will realize that these techniques can be applied to a variety of compounds in various contexts.

5 Example 1

 The lipid composition of the present invention contains a particular mix of phospholipids. We have found that increased sustained release times may be obtained by using this phospholipid composition. The phospholipid composition of the present invention can be derived from egg lecithin. The composition contains
10 phosphatidylcholine and a substantial amount of phosphatidylethanolamine. It also contains other lipids such as steroids, di- and tri- glycerides, and other fatty acids. The present method allows for the extraction of a lipid mixture which is useful for practicing the present invention at a cost which is substantially less than those previously available.

 To extract the phospholipid mixture which may be employed in the present
15 invention, we performed a lipid extraction procedure which began with dehydrated yolk from chicken eggs. The yolk material was extracted once with acetone, followed by one extraction with ethyl alcohol. The solvents were removed and the remaining syrup was analyzed by gas chromatography/mass spectroscopy. Of the syrup obtained, 90% was found to be solids.

20 Approximately 70% of the phospholipid syrup material was lipid. At least 50% of the lipids were phosphatidylcholine and at least 15% was phosphatidylethanolamine. The remainder were other lipids. While these are typical compositions, more or less of these materials may be present. For example, we found that phosphatidylcholine sometimes comprised up to 68% of the lipid material, and phosphatidylethanolamine can comprise as
25 little as 10% or 15% or as much as 25% of the lipid material. The actual amounts may vary depending on a variety of factors which are normal and expected in chemical processes, such as the technique of the operator.

Example 2

 This example illustrates the method whereby microcrystals containing
30 oxytetracycline were prepared.

 The formula for making the microcrystals was as follows:

oxytetracycline (OTC)	25% w/v
phospholipid syrup	20% w/v
(from Example 1)	

WO 00/27369

PCT/US99/26452

15

mannitol USP	2.25%
methylparaben NF	0.18%
propylparaben NF	0.02%
Water for Injection	QS

5 Referring to Fig. 1 throughout this example, water for injection (WFI) USP, was added to a 3,000 L stainless steel formulation tank to approximately 40% of target final tank batch volume at a temperature of not more than 32°C (10). Mannitol USP was added and the ingredients mixed until the mannitol dissolved. WFI was then added to 45% of final tank batch volume, and the solution mixed for at least 10 minutes. Mannitol was
10 tested for and whenever necessary, increments of mannitol or WFI were added to achieve a final mannitol concentration of 2.25% (w/v). Suspension recirculation was then initiated (20).

Methylparaben NF, propylparaben NF, phospholipids syrup (see Example 1), and oxytetracycline were added with continuous recirculation. The solution was mixed for a
15 minimum of 30 minutes until the suspension appeared to be creamy without any clumps of raw material. WFI was added to the target final batch volume and mixed for at least 15 minutes. We note that the mannitol and paraben were first mixed with WFI using less than the total expected amount of water. We then added the phospholipids syrup which went readily into solution. The OTC powder was then blended into this liquid. We then
20 QS'ed the final volume of water to have a complete "pre-mix" for processing through a Gaulin Homogenizer for three complete passes, as explained below (20).

The suspension was cooled to not more than 70°F. Discrete pass 1 (30) was performed by passing the suspension from one mixing tank through the homogenizer into a second mixing tank at 10,000 psi (stage 1 valve) and 500 psi (stage 2 valve). The pH
25 may be measured and adjusted if necessary with 10N sodium hydroxide and/or 5 N HCl. The formulation may be tested for oxytetracycline and adjusted if necessary (40).

The solution is again cooled to not more than 70°F. Discrete pass 2 (50) is performed by passing the suspension from one mixing tank through the homogenizer into the second tank at 10,000 psi (stage 1 valve) and 500 psi (stage 2 valve).

30 The suspension was cooled to not more than 70°F. Discrete pass 3 (60) was performed by passing the suspension from one mixing tank through the homogenizer into the second tank at 10,000 (stage 1 valve) and 500 psi (stage 2 valve). The pH may then be measured and adjusted with 10 N sodium hydroxide and/or 5 N HCl, if required (70).

The suspension is aliquoted into containers of appropriate size (80), visually
35 inspected (90), packed for shipping (100), and may be sterilized by gamma irradiation (110). We have found that, in the case of oxytetracycline, it is desirable to use from 20

WO 00/27369

PCT/US99/26452

16

kilogreys to 40 kilogreys of radiation to accomplish the sterilization procedure. Finished product testing may then be performed (120). The process here disclosed produces phospholipid-coated microcrystals containing antibiotic in an aqueous suspension. In the case of oxytetracycline, the drug is administered once to produce therapeutic blood and tissue levels of oxytetracycline for 12 days in cows.

While this example illustrates the manufacture of oxytetracycline on a large scale, the same principles can be followed to produce microcrystals of various pharmacologically active compounds. The person of skill in the art will understand that minor modifications to this technique may be required for other compounds.

10 Example 3

This example illustrates the injection of various dosages of microcrystals containing OTC into cattle and the levels of OTC achieved in serum and lung tissue. Sustained release of OTC and tissue residue depletion data are also illustrated.

A sample of an oxytetracycline microcrystal suspension was manufactured in accordance with Example 2, and potency was measured at 250 mg/ml. Suspension formulation dosages of 22 mg/lb animal weight, 16 mg/lb, and 10 mg/lb were subcutaneously injected into healthy beef cattle which weighed from 734-764 lbs. Figure 2 shows the mean serum and lung tissue concentrations of OTC as a function of time. The OTC blood concentrations reached peak levels of 3.7 ppm at 54 hrs. Depletion rates appeared fairly similar among the dosage levels. Even at 10 days post-dose there were relatively significant serum OTC concentrations; 0.2, 0.3 and 0.6 ppm for the 10, 16 and 22 mg/lb dosages, respectively.

We also examined tissue residue depletion of OTC administered subcutaneously in healthy calves at a target dose rate of 22 mg OTC/lb body weight in order to determine whether effective quantities of the drug were actually present in body tissue. Group average body weights on the day of drug treatment were between 587-632 lbs. Lung tissue levels averaged 2.18 ppm at 3 days withdrawal and declined progressively through the last sampling point at 12 days postdose, when levels averaged 0.55 ppm.

We therefore unexpectedly found serum OTC concentrations at effective levels as late as 10 days post-dose, several days longer than those attainable with previously known compositions.

The following examples illustrate that the compositions of the present invention have the ability to sharply reduce the toxicity of drugs. Tilimicosin is generally not used in dogs, cats, or pigs, because of concerns about the toxicity of this drug compound. Treatment of these animals with effective doses of tilimicosin may result in the death of

WO 00/27369

PCT/US99/26452

17

these animals. Flunixin is generally not used in cats, also because of concerns over toxicity. Flunixin is sometimes used with hesitancy in dogs, but is also surrounded by the same toxicity concerns. It is noted that treatment of these animals with dosages of only one-half of those described below is capable of causing the death of these animals.

5 Example 4 – Use of Oxytetracycline Microcrystals in Horses

 This example illustrates that microcrystals containing 25% oxytetracycline were safely injected into horses at a dosage as high as 16 mg/lb.

 While oxytetracycline is commonly used to treat Potomac fever in horses, the administration of OTC in horses presents the danger of killing the animal if the drug is
10 administered too quickly, as OTC may interact with and lyse the white blood cells and cause severe shock in the animal. Therefore, there exists a need for a safer mode of administering medications of this type to horses and other mammals.

 25% OTC microcrystals were injected subcutaneously and intra-muscularly into healthy horses. This was found to cause temporary sore muscles in the horses, but no
15 other adverse effects were observed. Therapeutic levels of OTC will be observed for up to 10 days.

 25% OTC microcrystals were also administered intravenously into horses at a dose of 14 mg/lb. No adverse effects were observed with this mode of administration, and statistical extrapolation revealed therapeutic levels of OTC will remain in the blood for at
20 least five days.

 25% OTC microcrystals were also administered intravenously at a dose of 16 mg/lb. No adverse effects were observed, and this dose will provide therapeutic levels of OTC for over five days.

 While not wanting to be bound by any particular theory or principle, it is believed
25 that the lipid coating of the microcrystal composition serves to form a protective barrier and protect the labile white blood cells from the OTC.

Example 5

 The small scale manufacture of tilmicisin is illustrated in Example 9 below. Tilmicisin can also be manufactured on a large scale by following the principles taught in
30 the examples above.

 This example discusses the results of injecting microcrystals containing tilmicisin into dogs, cats, and pigs and the subsequent analysis of body tissues for tilmicisin content. It is illustrated that another benefit of the present invention is that compounds which are otherwise too toxic to be safely administered to animals can be safely administered after

WO 00/27369

PCT/US99/26452

18

being coated with the phospholipid compositions of the present invention. In the present embodiment, the invention enables the animal caretaker to take advantage of this very effective antibiotic.

Two dogs (1 male and 1 female) were injected subcutaneously with microcrystals
5 containing tilmicosin at a dose rate of 10 mg/kg. Two other dogs (1 male and 1 female)
were injected subcutaneously with microcrystals containing tilmicosin at a dose rate of 20
mg/kg. On the sixth day, lungs, trachea, kidneys, jejunum, samples of dorsal and ventral
skin, and a piece of latissimus dorsi muscle were harvested from all animals and a control.
Levels of tilmicosin were found in the blood pellet to be greater than 0.5 ppm for about 4.5
10 days. None of the dogs exhibited any serious negative reactions to the drug. Figure 3
illustrates levels of tilmicosin in the blood serum and Figure 4 illustrates levels of
tilmicosin in the blood pellet. These figures show the drug associated with the blood cells,
and not the serum. "Blood serum" refers to the liquid portion of blood which remains
after at least a substantial portion of the blood cells and clotting proteins have been
15 removed. "Blood Pellet" refers to the portion of blood which forms as a pellet following
precipitation of at least a substantial portion of the clotting proteins and blood cells
following centrifugation.

Levels of tilmicosin in the various tissues are illustrated in Figure 5. This figure
shows that high levels of tilmicosin are found in the variety of tissues studied after six
20 days. These results show that the tilmicosin was moving from the blood cells and into the
various body tissues.

Two pigs were injected intramuscularly with a dose of 20 mg/kg of microcrystals
containing tilmicosin. On the sixth day, lungs, trachea, kidneys, jejunum, samples of
dorsal and ventral skin, and a piece of latissimus dorsi muscle were harvested from both
25 animals and a control. Levels of tilmicosin found in the tissues are illustrated in Figure 5.
None of the pigs died as a result of the tilmicosin administration, despite the high dose
used.

Two female cats were injected subcutaneously in the dorsal cervical area with a
dose of 20 mg/kg of microcrystals containing tilmicosin. No abnormalities were observed
30 over the six-day in-life observation period. On the sixth day, lungs, trachea, kidneys,
jejunum, samples of dorsal and ventral skin, and a piece of latissimus dorsi muscle were
harvested. Levels of tilmicosin found in the tissues are illustrated in Figure 5.

WO 00/27369

PCT/US99/26452

19

Example 6 – The Use of Tilmicosin Microcrystals to Treat Kennel Cough in Puppies

This example discusses how microcrystals containing tilmicosin were used to treat “kennel cough” in puppies with success. This example also describes a comparison of therapy with tilmicosin microcrystals versus conventional therapy with amoxicillin.

5 Kennel cough is often accompanied by nasal discharge and cough and is suspected to be of *Bordetella bronchiseptica* origin. Present methods of treating kennel cough suffer from a high incidence of lack of compliance with the requirements of the therapy on the part of the animal owner. Therefore, the present method which offers a therapy which can be administered once a week by an animal caretaker finds great utility. In many instances,
10 complete recovery from the disease will be accomplished with a single administration of the microcrystals suspension.

Five to seven week old puppies of various breeds were used. All were currently showing nasal discharge and some degree of cough on tracheal palpation. Nine puppies were placed in each treatment group.

15 Puppies in the tilmicosin microcrystals group were dosed at 20 mg/kg in a single subcutaneous injection between the shoulder blades. No serious reactions were observed at the injection sites of puppies treated with tilmicosin microcrystals.

Puppies in the amoxicillin group were treated with Amoxi Drops® (Pfizer) at the recommended dosage of 5 mg/lb twice daily orally. Puppies under 2.5 lbs were given .25
20 cc of 50 mg/cc suspension, and puppies 2.5 lbs - 5 lbs were given .50 cc of 50 mg/cc suspension. The owner was instructed to repeat the dosage twice daily for the entire week.

After seven days, the puppies were examined. All puppies in the tilmicosin microcrystals group showed no nasal discharge of any type. One puppy still had a very mild cough at this time on tracheal palpation. Six puppies in the amoxicillin group still
25 showed nasal discharge to some degree.

Example 7 – The Use of Tilmicosin Microcrystals to Treat Respiratory Disease in Cats

This example illustrates how 20% Tilmicosin microcrystals were used to treat upper respiratory infections in cats.

30 Three cats with upper respiratory infections that were suspected to be at least partially bacterial were selected for study. The cats were healthy except for the respiratory disease and had no history of previous drug reactions. One cat was treated with tilmicosin microcrystals and was injected subcutaneously in the dorsal cervical area using aseptic technique at a dose of 20 mg/kg. The second cat was treated with clavimox®, which is an approved antibiotic with a label indication for upper respiratory disease. The third cat was
35 untreated.

WO 00/27369

PCT/US99/26452

20

At the end of seven days the cats were evaluated. The cat treated with tilmicosin microcrystals showed no remaining symptoms. Eyes and nose were clear, and no sneezing or coughing was observed or reported by the owner.

The cat treated with clavimox® showed mild sneezing and/or cough and an elevation in rectal temperature of less than one degree. Ocular and/or nasal discharge was either mild or absent.

The untreated cat showed severe sneezing and coughing, elevated body temperature, and a very evident discharge from the eyes and nose. Appetite was diminished or absent.

10 Example 8 – Safe Injection of Flunixin Microcrystals in Dogs and Cats

This example illustrates that microcrystals containing flunixin can be safely injected into dogs and cats.

Two dogs and two cats (both groups containing one male and one female) were selected for study. The animals were injected subcutaneously between the shoulder blades at a dose rate of 20 mg/kg of body weight at Day 0. The animals were observed daily for seven days for signs of toxicity and general health. The female cat had diarrhea on days 2-4. No other abnormalities were observed in any of the other animals.

Example 9 – Safe Injection of Cefoperozone Microcrystals in Dogs and Cats

This example illustrates that microcrystals containing cefoperozone can be safely injected into dogs and cats.

Two dogs and two cats (both groups containing one male and one female) were selected for study. The animals were injected subcutaneously between the shoulder blades at a dose rate of 20 mg/kg of body weight at Day 0. The animals were observed for signs of toxicity and general health for seven days. No abnormalities were observed in any of the animals.

The following examples illustrate how the manufacturing technology was applied to manufacture microcrystals containing various pharmacologically active compounds on a small scale, using a laboratory scale sonicator or small volume microfluidizer.

The manufacture of microcrystals containing several pharmacologically active compounds is illustrated in the examples set forth below. The examples illustrate some of the problems which may be encountered in working with a particular drug, and solutions which were devised. The person of skill in the art will see that these solutions, and others which are known in the art, can be applied to successfully manufacture microcrystals of a wide variety of water insoluble compounds.

WO 00/27369

PCT/US99/26452

21

Those skilled in the art also know of the various techniques which may be applied to cause water soluble compounds to behave more like water insoluble compounds. Therefore, these techniques can also be applied to the manufacture of some water soluble compounds.

5 Example 10 – Preparation of Microcrystals Containing Flunixin

11 mg of flunixin was placed into 10 ml of water with good stirring provided by a magnetic stir bar. Very little of the material went into solution even after 10 minutes stirring. The volume was raised to 30 ml with water and less than half of the crystals dissolved into solution. The pH of the suspension was 3.4. The suspension was then
10 titrated to pH 8.4 which caused a change in the shape of the clumps of crystals into floculates on the top of the water but all of the material still did not dissolve.

A flunixin microcrystal suspension was prepared in the following manner; In a 500 ml beaker 90 ml of 300 mM mannitol, 2 mM sodium phosphate buffer was mixed with 30 grams of flunixin and 30 grams phospholipids syrup. The preparation was blended using
15 an Omni GLH homogenizer (which operates according to a “chop and blend” principle) with a medium probe while titrating to pH 5.2. The preparation was then passed through a M-110F Microfluidizer from Microfluidics Corporation, using an inlet pressure of 55 psi resulting in an internal pressure of 1400 psi. An ice water cooling coil bath was used on the outlet port of the microfluidizer to prevent the build up of heat in the preparation.
20 After about 4 passes through the microfluidizer the preparation creamed and became thick. The mixture was then sonicated and an additional 7.5 grams of phospholipids syrup was added to the preparation. After further processing the product demonstrated aggregation of crystals under microscopy. Several more additions of phospholipids syrup were made during processing for a total of 17 grams of additional phospholipid syrup added. The final
25 product appeared to be a homogenous mixture of small crystals that had some tendency to aggregate but with an average particle size of less than 3µm by microscopy.

Example 11 – Preparation of Microcrystals of Tilimicosin

A 20% tilimicosin microcrystal preparation was made in the following manner; In a 500 ml beaker 42.4 grams of tilimicosin was mixed with 40 grams of phospholipid syrup
30 and 120 ml of 300 mM mannitol, 2 mM sodium phosphate buffer at pH 8.2. The mixture was then blended using an Omni GLH homogenizer with a medium probe. The pH of the preparation went to 9.07 and was allowed to remain there. The preparation was then passed a total of 7 times through a M-110F Microfluidizer from Microfluidics Corporation, using an inlet pressure of 55 psi resulting in an internal pressure of 1400 psi.

WO 00/27369

PCT/US99/26452

22

An ice water cooling coil bath was used on the outlet port of the microfluidizer to prevent the buildup of heat in the preparation. The final product appeared as a homogeneous off white suspension of small free flowing crystals with an average particle size of less than 3 μ m by microscopy.

5 Example 12 – Preparation of Cephalone Microcrystals

A preparation of cephalone microcrystals was made in the following manner. 30 grams of phospholipids syrup were hydrated in 90 ml of 300 mM mannitol, 2 mM sodium phosphate pH 8.2 for 30 minutes. The mixture was then blended using an Omni GLH homogenizer for 5 minutes while titrating to a pH of 7.10. Next 30 grams of cephalone
10 was added to the preparation and the mixture was blended and titrated to pH 6.75. The mixture was then passed a total of seven times through a M-110F Microfluidizer from Microfluidics Corporation, using an inlet pressure of 55 psi resulting in an internal pressure of 1100 psi. An ice water cooling coil bath was used on the outlet port of the Microfluidizer to prevent the build up of heat in the preparation. The preparation appeared
15 as a homogeneous mixture with a average particle size of less than 3 microns by microscopy.

Example 13 – Preparation of Nitazoxanide Microcrystals

A preparation of nitazoxanide microcrystals was made in the following manner: 30 grams of phospholipids syrup were hydrated in 90 ml of 300 mM mannitol, 2 mM sodium
20 phosphate pH 8.2 for 30 minutes. The mixture was then blended using a Omni GLH homogenizer for 5 minutes while titrating to a pH of 5.14. Next 30 grams of nitazoxanide was added to the preparation and the mixture was blended and titrated to pH 5.02. The mixture was then passed a total of seven times through a M-110F Microfluidizer from Microfluidics Corporation, using an inlet pressure of 55 psi resulting in an internal
25 pressure of 1100 psi. An ice water cooling coil bath was used on the outlet port of the microfluidizer to prevent the build up of heat in the preparation. The preparation appeared as a homogeneous mixture with a average particle size of less than 3 μ m by microscopy.

Example 14 – Preparation of 20% Ofloxacin Microcrystals

A preparation of 20% ofloxacin microcrystals was obtained in the following
30 manner: In a 500 ml beaker 40 grams of ofloxacin was mixed with 40 grams of phospholipids syrup and 120 ml of 300 mM mannitol, 2 mM sodium phosphate buffer at pH 8.2. The mixture was then blended using an Omni GLH homogenizer with a medium probe. The pH of the preparation went to 7.06 and was allowed to remain there. The

WO 00/27369

PCT/US99/26452

23

preparation was then passed a total of seven times through a M-110F Microfluidizer from Microfluidics Corporation, using an inlet pressure of 55 psi resulting in an internal pressure of 1400 psi. An ice water cooling coil bath was used on the outlet port of the microfluidizer to prevent the build up of heat in the preparation. The final product
5 appeared as a homogeneous milky white suspension of small free flowing crystals with an average particle size of less than 3 μm by microscopy.

Example 15 – Preparation of Cefquinolone Microcrystals

30 grams of phospholipid syrup (see Example 1) was hydrated in 90 ml of 300 mM mannitol, 2 mM sodium phosphate, pH 8.2 for 30 minutes. The mixture was then blended
10 using an Omni GLH homogenizer for five minutes while titrating to a pH of 7.10. 30 grams of cefquinolone was then added to the preparation and the mixture was blended and titrated to pH 6.75. The mixture was then passed a total of seven times through an M-110F Microfluidizer from Microfluidics Corporation, using an inlet pressure of 55 psi resulting in an internal pressure of 1100 psi. An ice water cooling coil bath was used on
15 the outlet port of the microfluidizer to prevent the build up of heat in the preparation. The preparation appeared as a homogeneous mixture with an average particle size of less than 3 μm by microscopy.

Example 16 – Preparation of Ofloxacin Microcrystals

In a 100 ml beaker, 4.8 grams of phospholipid syrup (see Example 1) was hydrated
20 in 38.3 ml of 300 mM mannitol, 2 mM sodium phosphate buffer at pH 8.2 for one hour, and then was blended using an Omni GLH homogenizer. Next 4.86 grams of ofloxacin was added to the preparation and the mixture was blended as above. The preparation was then sonicated for 30 minutes using a Sonifier Cell Disrupter from Heat Systems Ultrasonics, cycling the sonicator off for one minute for every 3 minutes sonication time
25 and keeping the preparation immersed in an ice water bath to prevent the build up of heat while being titrated to a pH of 6.87. The resulting preparation appeared as a milky white suspension and had an average particle size of less than 3 μm .

Example 17 – Preparation of Microcrystals of Cefoperazone

15 mg of cefoperazone acid was placed in 10 ml of water with good stirring
30 supplied by a magnetic stir bar. Some of the material seemed to dissolve but there was still evidence of undissolved material even after 30 minutes stirring. The suspension resulted in a pH of 3.3. The volume was raised to 30 ml with water and very little more of

WO 00/27369

PCT/US99/26452

24

the precipitate dissolved and the pH remained the same. The suspension was then titrated to pH 8.2 with 50 μ l of 1 M NaOH and there was still evidence of undissolved material.

5 A preparation of cefoperazone microcrystals was prepared in the following manner; In a 50 ml beaker, 3.0 grams of phospholipids syrup and 6.0 grams of cefoperazone acid was added slowly to 21 ml of 300 mM mannitol, 2 mM sodium phosphate buffer at pH 8.2 with intermittent sonication supplied by a Sonifier Cell Disrupter from Heat Systems Ultrasonics. The preparation was then sonicated for 10 minutes, cycling the sonicator off for one minute for every 3 minutes sonication time and keeping the preparation immersed in an ice water bath to prevent the build up of heat
10 while being titrated to a pH 4.47. Further additions of 3 grams cefoperazone and 1.5 grams phospholipids syrup were made and sonication was continued for another 20 minutes. The resulting preparation appeared as a milky white suspension and had an average particle size of less than 3 μ m by microscopy with less than 10% of the material greater than 3 μ m.

15 While many examples and embodiments of the present invention have been shown and described herein, various modifications may be made without departing from the scope of the present invention, and all such modifications and equivalents are intended to be covered.

Other embodiments of this invention are disclosed in the following claims.

WO 00/27369

PCT/US99/26452

25

Claims

1. A composition of lipids for use in coating a pharmacologically active compound, said composition comprising,
from about 40 percent to about 80 percent by weight phosphatidylcholine;
5 and
from about 10 percent to about 30 percent by weight phosphatidylethanolamine.
2. Composition of lipids for use in coating a pharmacologically active compound, said composition comprising,
10 from about 50 percent to about 68 percent by weight phosphatidylcholine; and
from about 15 percent to about 25 percent by weight phosphatidylethanolamine.
3. A pharmaceutical composition, comprising a plurality of microcrystals,
15 said microcrystals comprising a pharmacologically active compound contained within a phospholipid layer, said phospholipid layer comprising the lipid composition of claim 1.
4. A pharmaceutical composition, comprising a plurality of microcrystals, said microcrystals comprising a pharmacologically active compound contained within a phospholipid layer, said phospholipid layer comprising the lipid composition of claim 2.
- 20 5. A pharmaceutical composition comprising, a plurality of microcrystals, said microcrystals comprising a pharmacologically active compound contained within a phospholipid layer;
wherein at least 50 percent of said microcrystals are from about 0.5 μm to about 3.0 μm in diameter; and
25 wherein at least about ten percent of said microcrystals are from about 3.0 μm to about 10 μm in diameter; and
wherein at least about 90% of said microcrystals are less than about 10 μm in diameter; and
said composition contains microcrystals that are greater than about 10 μm
30 in diameter.

WO 00/27369

PCT/US99/26452

26

6. A composition according to claim 5, wherein
at least fifty percent of said microcrystals are from about 0.5 μm to about
3.0 μm in diameter; and
from about thirty to about forty percent of said microcrystals are from
5 about 3.0 μm to about 10 μm in diameter; and
said composition contains microcrystals which are greater than about 10
 μm in diameter.

7. A method for manufacturing a pharmaceutical composition for the
10 sustained release of a pharmacologically active compound, said pharmaceutical
composition comprising a plurality of microcrystals which comprise a pharmacologically
active compound contained within a phospholipid layer, said method comprising the steps
of:

forming a lipid suspension comprising the pharmacologically active
15 compound; and

passing said lipid suspension containing said pharmacologically active
compound through a homogenizer at high pressure to coat said pharmacologically active
composition with said lipid suspension and produce a composition of microcrystals
wherein

20 at least about 50 percent of said microcrystals are from about 0.5 μm to
about 3 μm in diameter; and

at least about ten percent of said microcrystals are from about 3 μm to
about 10 μm in diameter; and

25 said composition contains microcrystals which are greater than about 10
 μm in diameter.

8. A method for manufacturing a pharmaceutical composition for the
sustained release of a pharmacologically active compound, said pharmaceutical
composition comprising a plurality of microcrystals which comprise a pharmacologically
active compound contained within a phospholipid layer, said method comprising the steps
30 of:

forming a lipid suspension; and
contacting said lipid suspension with said pharmacologically active
compound to coat said pharmacologically active compound with said lipid suspension and
produce a composition of microcrystals wherein

WO 00/27369

PCT/US99/26452

27

at least about 50 percent of said microcrystals are from about 0.5 μm to about 3 μm in diameter; and

at least about ten percent of said microcrystals are from about 3 μm to about 10 μm in diameter; and

5 said composition contains microcrystals which are larger than about 10 μm in diameter.

9. The method of claims 7 or 8, wherein at least about twenty five percent of said microcrystals are greater than about 3 μm in diameter.

10 10. The method of claim 7, wherein the lipid suspension is passed through said homogenizer a plurality of times.

11. The method of claim 10, wherein the lipid suspension is passed through said homogenizer three times.

12. The method of claims 7 or 8, wherein said pharmacologically active compound is an antibiotic.

15 13. The method of claim 12, wherein said antibiotic is oxytetracycline.

14. The method of claim 12, wherein said antibiotic is tilmicosin.

15. The method of claim 12, wherein said antibiotic is a floroquinolone and a cephalosporin combined to form a single molecule.

16. The method of claim 12, wherein said antibiotic is a floroquinolone.

20 17. The method of claim 16, wherein said floroquinolone is ofloxacin.

18. The method of claim 16, wherein said floroquinolone is sarafloxacin.

19. The method of claim 16, wherein said floroquinolone is ciprofloxacin.

20. The method of claim 12, wherein said antibiotic is a cephalosporin.

WO 00/27369

PCT/US99/26452

28

21. The method of claim 20, wherein said cephalosporin is cefazolin.
22. The method of claim 20, wherein said cephalosporin is cefuroxime or a derivative of cefuroxime.
23. The method of claim 20, wherein said cephalosporin is cefoperazone.
- 5 24. The method of claim 20, wherein said cephalosporin is cefaclor.
25. The method of claim 12, wherein said antibiotic is nitazoxanide.
26. The method of claim 7 or 8, wherein said pharmacologically active compound is an anesthetic.
- 10 27. The method of claims 7 or 8, wherein said pharmacologically active compound is an anesthetic.
28. The method of either of claim 27, wherein said anesthetic is propofol.
29. The method of claims 7 or 8, wherein said pharmacologically active compound is an anti-inflammatory agent.
30. The method of claim 29, wherein said anti-inflammatory agent is flunixin.
- 15 31. The method of claims 7 or 8, wherein said pharmacologically active compound is an anti-protozoan agent.
32. The method of claim 31, wherein said anti-protozoan agent is nitazoxanide.
33. The method of claims 7 or 8, further comprising the step of sterilizing said composition of microcrystals.
- 20 34. The method of claim 33, wherein said step of sterilizing said composition of microcrystals comprises the use of gamma radiation to sterilize said composition.
35. A method for treating an infection in a mammal comprising the steps of:

WO 00/27369

PCT/US99/26452

29

administering to the mammal to be treated an effective dose of a composition comprising a plurality of microcrystals, said microcrystals comprising an antibiotic contained within a phospholipid layer;

wherein at least about 50 percent of said microcrystals are from about 0.5 μm to about 3.0 μm in diameter; and

wherein at least about ten percent of said microcrystals are from about 3.0 μm to about 10 μm in diameter; and

said composition contains microcrystals that are larger than about 10 μm in diameter.

36. The method of claim 35, wherein said antibiotic is selected from the group consisting of: oxytetracycline, tilmicosin, cephalone, a floroquinolone, a cephalosporin, or nitazoxanide.

37. The method of claim 35, wherein said composition is administered to the mammal to be treated by parenteral administration.

38. The method of claim 36, wherein said antibiotic is selected from the group consisting of: oxytetracycline, tilmicosin, cephalone, a floroquinolone, a cephalosporin, or nitazoxanide.

39. The method of claims 35-37, wherein said mammal is a bovine.

40. The method of claims 35-37, wherein said mammal is an equine.

41. The method of claims 35-37, wherein said mammal is a porcine.

42. The method of claims 35-37, wherein said mammal is a canine.

43. The method of claims 35-37, wherein said mammal is a feline.

44. The method of claims 35-37, wherein said infection is caused by a protozoan.

45. A method for treating respiratory disease in a mammal comprising the steps of:

WO 00/27369

PCT/US99/26452

30

administering to the mammal to be treated an effective dose of a composition comprising a plurality of microcrystals, said microcrystals comprising an antibiotic contained within a phospholipid layer;

wherein at least about 50 percent of said microcrystals are from about 0.5
5 μm to about 3.0 μm in diameter; and

wherein at least about ten percent of said microcrystals are from about 3.0
 μm to about 10 μm in diameter; and

said composition contains microcrystals that are larger than about 10 μm in
diameter.

10 46. The method of claim 45, wherein said antibiotic is selected from the group consisting of: oxytetracycline, tilmicosin, cephalone, a fluoroquinolone, a cephalosporin, or nitazoxanide.

47. The method of claim 45, wherein said composition is administered to the mammal to be treated by parenteral administration.

15 48. The method of claim 47, wherein said antibiotic is selected from the group consisting of: oxytetracycline, tilmicosin, cephalone, a fluoroquinolone, a cephalosporin, or nitazoxanide.

49. The method of claims 46-48, wherein said mammal is a bovine.

20 50. The method of claims 46-48, wherein said respiratory disease is bovine respiratory disease.

51. The method of claim 46-48, wherein said microcrystals contain oxytetracycline.

52. The method of claims 46-48, wherein said mammal is an equine.

53. The method of claims 46-48, wherein said mammal is a porcine.

25 54. The method of claims 46-48, wherein said mammal is a canine.

55. The method of claims 46-48, wherein said mammal is a feline.

WO 00/27369

PCT/US99/26452

31

56. A method for treating inflammation in a mammal comprising the steps of:
administering to the mammal to be treated an effective dose of a
composition comprising a plurality of microcrystals, said microcrystals comprising an
anti-inflammatory agent contained within a phospholipid layer;
5 wherein at least about 50 percent of said microcrystals are from about 0.5
 μm to about 3.0 μm in diameter; and
wherein at least about ten percent of said microcrystals are from about 3.0
 μm to about 10 μm in diameter; and
said composition contains microcrystals that are larger than about 10 μm in
10 diameter.
57. The method of claim 43, wherein said composition is administered to the
mammal to be treated by parenteral administration.
58. The method of claims 56 or 57, wherein said anti-inflammatory agent is
flunixin.
- 15 59. A method for treating pain in a mammal comprising the steps of:
administering to the mammal to be treated an effective dose of a
composition comprising a plurality of microcrystals, said microcrystals comprising an
anesthetic contained within a phospholipid layer;
wherein at least about 50 percent of said microcrystals are from about 0.5
20 μm to about 3.0 μm in diameter; and
wherein at least about ten percent of said microcrystals are from about 3.0
 μm to about 10 μm in diameter; and
said composition contains microcrystals that are larger than about 10 μm in
diameter.
- 25 60. The method of claim 59, wherein said composition is administered to the
mammal to be treated by parenteral administration.
61. The method of claims 59 or 60, wherein said anesthetic is propofol.
62. A method for isolating from egg yolk a composition of lipids suitable for
coating microcrystals, comprising the steps of,
30 performing a lipid extraction on said egg yolk with acetone; and

WO 00/27369

PCT/US99/26452

32

performing a lipid extraction on said egg yolk with ethyl alcohol.

63. A pharmaceutical composition comprising a plurality of microcrystals, said microcrystals comprising,
from about 10 percent to about 30 percent by weight of a
5 pharmacologically active compound; and
from about 15 percent to about 30 percent by weight of a phospholipid
syrup.

64. The pharmaceutical composition of claim 63, wherein said microcrystals
comprise from about 25 to about 30 percent by weight of a pharmacologically active
10 compound; and
about 20 percent by weight of a phospholipid syrup.


65. The pharmaceutical composition of claims 63 or 64, wherein said
pharmacologically active compound is an antibiotic.

66. The pharmaceutical composition of claim 65, wherein said antibiotic is
15 oxytetracycline.

WO 00/27369

PCT/US99/26452

01/05

*Fig.1*

WO 00/27369

PCT/US99/26452

02/05




Fig. 2

WO 00/27369

PCT/US99/26452

03/05




Fig. 3

WO 00/27369

PCT/US99/26452

04/05

TILMICOSIN IN BLOOD PELLET




Fig. 4


WO 00/27369

PCT/US99/26452

05/05

TILMICOSIN IN ANIMAL TISSUE

TISSUE	ANIMAL	PPM	TISSUE	ANIMAL	PPM
LUNG (1)	DOG	0.682	SKIN (1)	DOG	1.072
LUNG (1)	PIG	0.840	SKIN (1)	PIG	1.063
LUNG (1)	CAT	0.936	SKIN (1)	CAT	1.057
LUNG (2)	DOG	0.925	SKIN (2)	DOG	0.822
LUNG (2)	PIG	0.972	SKIN (2)	PIG	0.848
KIDNEY	DOG	0.937	SKIN (2)	CAT	0.808
KIDNEY	PIG	1.036	LASSISSIMUS DORSI	DOG	1.147
KIDNEY	CAT	1.122	LASSISSIMUS DORSI	PIG	1.147
			LASSISSIMUS DORSI	CAT	1.500



LEGEND (TYPE OF TISSUE)

1=LUNG(1) 2=LUNG(2) 3=KIDNEY 4=SKIN(1) 5=SKIN(2) 6=LASSISSIMUS DORSI

Fig. 5

INTERNATIONAL SEARCH REPORT

Inter. Appl. No.

PCT/US 99/26452

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/50 A61K9/14 A61K9/127 A61K47/24 A61K31/65
 A61K31/706 A61K31/538 A61K31/496 A61K31/545 A61K31/546
 A61K31/425 A61K31/05 A61K31/44 A61P31/00 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 091 188 A (HAYNES DUNCAN H) 25 February 1992 (1992-02-25) cited in the application	5-9, 12, 13, 26, 27, 29, 35-38, 45-48, 51, 56, 57, 59, 60, 63-66
Y	column 8, line 16 - line 35 column 11, line 20 - line 68 claims 1-7, 12; examples 1-12	5-13, 26, 27, 29, 35-38, 45-48, 51, 56, 57, 59, 60, 63-66



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

14 March 2000

Date of mailing of the international search report

21/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx 31 651 epo nl,
 Fax: (+31-70) 340-3018

Authorized officer

Epskamp, S

INTERNATIONAL SEARCH REPORT

Inter. Appl. No.
PCT/US 99/26452

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 16643 A (PHARMA LOGIC INC ; U S ARMY MEDICAL RESEARCH AND (US)) 6 June 1996 (1996-06-06) page 4, line 7 - line 15	63,65,66
Y	page 10, line 13 - line 21 examples 1,3; table 2	5-13,26, 27,29, 35-38, 45-48, 51,56, 57,59, 60,63-66
X	GB 2 046 094 A (NATTERMANN A & CIE) 12 November 1980 (1980-11-12) page 1, line 75 - line 116 page 2, line 7 - line 30 claims; examples	1-4,63
X	DATABASE WPI Section Ch, Week 198927 Derwent Publications Ltd., London, GB; Class B05, AN 1989-195153 XP002132736 & JP 01 131189 A (NIPPON OILS & FATS CO LTD), 24 May 1989 (1989-05-24) abstract	1,2,62

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 26452

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 35-61 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 8.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99 26452

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-4

Composition of lipids comprising 40-80% (w/w) phosphatidylcholine and 10-30% (w/w) phosphatidylethanolamine; Pharmaceutical composition comprising microcrystals comprising a pharmacologically active compound contained within a layer of said composition of lipids.

2. Claims: 5-61

Pharmaceutical composition comprising microcrystals comprising a pharmacologically active compound contained within a phospholipid layer, wherein at least 50% of said microcrystals are 0.5-3.0 micron in diameter, and wherein at least 10% of said microcrystals are 3.0-10 micron in diameter, and wherein at least 90% of said microcrystals are less than 10 micron in diameter, said composition contains microcrystals that are greater than about 10 micron; Method for manufacturing said pharmaceutical composition; Methods for treating a mammal comprising the step of administering said pharmaceutical composition.

3. Claim : 62

Method of isolating from egg yolk a composition of lipids suitable for coating microcrystals.

4. Claims: 63-66

Pharmaceutical composition comprising microcrystals comprising 10-30% (w/w) pharmacologically active compound and 15-30% (w/w) phospholipid syrup.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/26452

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5091188 A	25-02-1992	AT 181234 T	15-07-1999
		AU 7852891 A	11-11-1991
		CA 2078990 A	27-10-1991
		DE 69131349 D	22-07-1999
		DE 69131349 T	18-11-1999
		EP 0533690 A	31-03-1993
		ES 2134776 T	16-10-1999
		IN 173056 A	05-02-1994
		KR 159114 B	01-12-1998
		MX 25532 A	01-10-1993
		RU 2100030 C	27-12-1997
		WO 9116068 A	31-10-1991
		US RE35338 E	24-09-1996
		US 5091187 A	25-02-1992
		US 5246707 A	21-09-1993
		ZA 9103122 A	29-04-1992
WO 9616643 A	06-06-1996	US 5660854 A	26-08-1997
		AU 698113 B	22-10-1998
		AU 4364096 A	19-06-1996
		CA 2206259 A	06-06-1996
		EP 0790823 A	27-08-1997
		JP 10511019 T	27-10-1998
		US 5972366 A	26-10-1999
GB 2046094 A	12-11-1980	DE 2914788 A	16-10-1980
		AT 369651 B	25-01-1983
		AU 539044 B	06-09-1984
		AU 5733180 A	16-10-1980
		BE 882731 A	31-07-1980
		CA 1144480 A	12-04-1983
		CH 642546 A	30-04-1984
		FR 2453644 A	07-11-1980
		IT 1148790 B	03-12-1986
		JP 1671396 C	12-06-1992
		JP 3037524 B	05-06-1991
		JP 55141407 A	05-11-1980
		NL 8002097 A	14-10-1980
		SE 451427 B	12-10-1987
		SE 8002714 A	12-10-1980
		US 4309421 A	05-01-1982
		ZA 8002157 A	27-05-1981
JP 1131189 A	24-05-1989	NONE	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.